Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...

According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

Who would have predicted that one of the hottest trends for beleaguered biotechs in 2025 would be to rebrand as a crypto company? | Who would have predicted that one of the hottest trends for ...

The U.S. Food and Drug Administration named Richard Pazdur, its longtime overseer of cancer therapies, as its top drug ...

OCT has transformed retinal practice, enhancing diagnostic accuracy and treatment efficiency while reducing reliance on ...

According to a recent publication by Ameco Research, the global Cancer Therapeutics Market continues to accelerate, driven by breakthrough innovations in immunotherapy, targeted therapies, and ...

New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from five medicines that Pharmac will fund from 1 December 2025.

A proposed move by the US Food and Drug Administration (FDA) to accelerate development and ease approval of biosimilars could lead Indian pharma to the forefront of a new global opportunity.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...